The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).L'invention concerne des formulations d'anticorps, y compris des anticorps monoclonaux formulés dans un tampon d'histidine-acétate, ainsi qu'une formulation comprenant un anticorps qui se lie au domaine II de HER2 (par exemple le pertuzumab), et une formulation comprenant un anticorps qui se lie à DR5 (par exemple l'apomab).
